ATNM:NYE-Actinium Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 8.96

Change

0.00 (0.00)%

Market Cap

USD 0.27B

Volume

0.53M

Analyst Target

USD 70.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-1.15 (-0.86%)

USD 567.03B
BHVN Biohaven Pharmaceutical Holdin..

-1.08 (-2.81%)

USD 3.39B
HTD John Hancock Tax Advantaged Di..

+0.07 (+0.34%)

USD 2.41B
DNA Ginkgo Bioworks Holdings

-0.03 (-3.98%)

USD 1.68B
RCUS Arcus Biosciences Inc

-0.56 (-3.21%)

USD 1.60B
NUVB Nuvation Bio Inc

-0.09 (-2.64%)

USD 0.80B
ADCT ADC Therapeutics SA

+0.01 (+0.24%)

USD 0.39B
PGP PIMCO Global StocksPLUS & Inco..

+0.03 (+0.39%)

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.28B
LCTX Lineage Cell Therapeutics Inc

+0.02 (+1.89%)

USD 0.20B

ETFs Containing ATNM

RJZ 0.00 % 0.75 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 76.38% 88% B+ 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.38% 89% A- 99% N/A
Trailing 12 Months  
Capital Gain 1.82% 65% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.82% 58% F 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.80% 73% C 79% B-
Dividend Return 14.80% 73% C 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 117.55% 24% F 6% D-
Risk Adjusted Return 12.59% 70% C- 36% F
Market Capitalization 0.27B 74% C 37% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector